Health Canada has approved the sale of Probuphine, a subdermal implant developed by Titan Pharmaceuticals (NASDAQ:TTNP), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counselling and psychosocial support.
Probuphine will be distributed in Canada by Knight Therapeutics (TSX:GUD), which signed an exclusive distribution and sublicense agreement with closely-held Braeburn Pharmaceuticals.
“The approval of Probuphine offers new hope in the fight against opioid dependence, a devastating public health crisis in Canada,” Knight CEO, Jonathan Goodman, said in a statement. “We look forward to working with all stakeholders to make Probuphine available to Canadian patients.”
